Cano E, Carmona R, Muñoz-Chápuli R. Wt1-expressing progenitors contribute to multiple tissues in the developing lung. Am J Physiol Lung Cell Mol Physiol 305: L322-L332, 2013. First published June 28, 2013 doi:10.1152 doi:10. /ajplung.00424.2012velop from paired endodermal outgrowths surrounded by a mesodermal mesenchyme. Part of this mesenchyme arises from epithelialmesenchymal transition of the mesothelium that lines the pulmonary buds. Previous studies have shown that this mesothelium-derived mesenchyme contributes to the smooth muscle of the pulmonary vessels, but its significance for lung morphogenesis and its developmental fate are still little known. We have studied this issue using the transgenic mouse model mWt1/IRES/GFP-Cre (Wt1 cre ) crossed with the Rosa26R-EYFP reporter mouse. In the developing lungs, Wt1, the Wilms' tumor suppressor gene, is specifically expressed in the embryonic mesothelium. In the embryos obtained from the crossbreeding, the Wt1-expressing cell lineage produces the yellow fluorescent protein (YFP), allowing for colocalization with differentiation markers. Wt1 cre -YFP cells were very abundant from the origin of the lung buds to postnatal stages, contributing significantly to pulmonary endothelial and smooth muscle cells, bronchial musculature, tracheal and bronchial cartilage, as well as CD34 ϩ fibroblast-like interstitial cells. Thus Wt1 cre -YFP mesenchymal cells show the very same differentiation potential as the splanchnopleural mesenchyme surrounding the lung buds. FSP1 ϩ fibroblast-like cells were always YFP Ϫ ; they expressed the common leukocyte antigen CD45 and were apparently recruited from circulating progenitors. We have also found defects in pulmonary development in Wt1 Ϫ/Ϫ embryos, which showed abnormally fused lung lobes, round-shaped and reduced pleural cavities, and diaphragmatic hernia. Our results suggest a novel role for the embryonic mesothelium-derived cells in lung morphogenesis and involve the Wilms' tumor suppressor gene in the development of this organ. pulmonary development; coelomic epithelium; mesothelium; Wilms' tumor suppressor gene THE DEVELOPMENT OF THE RESPIRATORY system was a key evolutionary event for the air-breathing vertebrates. Lungs arose as specialized endodermal sacs from the digestive tract, and this phylogenetic origin is recapitulated in lung ontogeny. The contribution of mesodermal cells to the endodermal structures is essential for pulmonary development and function. In mouse embryos, the lung primordium sprouts from the ventral foregut by embryonic day (E) 9.5. It consists of a simple tube of endodermal epithelium surrounded by mesenchyme derived from the splanchnic mesoderm and lined by a layer of mesothelium. This primary tube branches in the pair of pulmonary sacs (reviewed in Ref. 17).
THE DEVELOPMENT OF THE RESPIRATORY system was a key evolutionary event for the air-breathing vertebrates. Lungs arose as specialized endodermal sacs from the digestive tract, and this phylogenetic origin is recapitulated in lung ontogeny. The contribution of mesodermal cells to the endodermal structures is essential for pulmonary development and function. In mouse embryos, the lung primordium sprouts from the ventral foregut by embryonic day (E) 9.5. It consists of a simple tube of endodermal epithelium surrounded by mesenchyme derived from the splanchnic mesoderm and lined by a layer of mesothelium. This primary tube branches in the pair of pulmonary sacs (reviewed in Ref. 17 ).
Pulmonary mesenchyme is essential for vascularization of the lungs. This process starts very early, around E10.5, once the systemic circulation has been established. Lung vascularization has been carefully described (10, 11) . Primitive capillary formation begins in the periphery of the lung by a process of vasculogenesis, i.e., migration and coalescence of angioblasts that will form vessels. During midgestation vascular growth is carried out by angiogenesis (1, 30, 36) . Besides this role in the vascularization of the lungs, the pulmonary mesenchyme also plays a fundamental role in lung morphogenesis given that this process is dependent on the crossed signals between endoderm and mesenchyme (6, 38, 40) . Endodermal Shh signals promote the proliferation of the mesenchyme, acting as a potent mitogen (3, 12, 23) . Fgf-10 is expressed in the splanchnic mesoderm surrounding buds in early stages of lung development and is essential for their formation (5, 37, 41) . Fgf-9 is expressed in the endodermal and coelomic epithelia, and it promotes proliferation of the mesenchyme, regulates Fgf-10, and maintains the Shh signal (38) . The null mutants for Fgf-10 and Fgf-9 die after birth with severe pulmonary defects (8, 26, 37, 43) . In all these studies, the pulmonary mesenchyme is considered an homogeneous population at least from the point of view of its mesodermal origin. However, at least an additional source of pulmonary mesenchyme has been demonstrated, originating through delamination of cells from the mesothelium lining the lung buds through an epithelial-mesenchymal transition (35) . This process has been described in other organs such as the heart (25, 31, 32) , the liver (19) , or the intestine (7) . With the exception of the vascular smooth muscle (35) , the contribution of this alternative source of mesenchyme to the different tissues of the developing lungs remains undetermined.
Since the Wilms' tumor suppressor gene Wt1 is specifically expressed in the embryonic mesothelium of the lung buds since their inception (35) , this gene is a reliable marker for the lineage of the cells derived from the mesothelium. We have developed a model based on the same Wt1-Cre system from other studies (9a, 42) using the Rosa26R-EYFP mouse line as a reporter. Yellow fluorescent protein (YFP) is highly expressed in all the Wt1-expressing cell lineage (that we will call herein Wt1 cre -YFP cells) and it could be easily colocalized with a number of cell differentiation markers. In this way, we have analyzed the fate and differentiation of cells derived from the coelomic mesothelium and their contribution to different pulmonary tissues. Since we have found that this contribution is quantitatively relevant, we have also studied the lung phenotype of the Wt1 Ϫ/Ϫ mouse embryos, and we have found hitherto undescribed defects that suggest a key role for Wt1 in pulmonary morphogenesis.
MATERIALS AND METHODS
The animals used in our research program were handled in compliance with the institutional and European Union guidelines for animal care and welfare. The procedure was approved by the Committee on the Ethics of Animal Experiments of the University of Málaga (procedure code 2009-0037). The mWt1/IRES/GFP-Cre (Wt1 Cre ) mouse has been used for previous studies of the Wt1 lineage (22, 37) . Homozygote (Cre ϩ/ϩ ) mice were crossed with Rosa26R-EYFP [B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J]. The WT470LacZ mice strain expressing LacZ under control of the human WT1 promoter was generated as previously described (28) . The Wt1 GFP/ ϩ knockin line (18) , in which the exon 1 of one Wt1 allele has been replaced by the GFP sequence, was also used as reporter of the Wt1 expression. Wt1 knockout mice (Wt1 Ϫ/Ϫ ) were generated by gene targeting, as previously described (21) .
Immunofluorescence and immunohistochemistry. Embryos were staged from the time point of vaginal plug observation, which was designated as the stage E0.5. Whole embryos and the viscera of neonates were excised, washed in PBS, and fixed in 4% fresh paraformaldehyde solution in PBS for 2-8 h. Then the embryos were washed in PBS, cryoprotected in sucrose solutions, embedded in OCT, and frozen in liquid N 2-cooled isopentane, and 10-m cryosections were stored at Ϫ20°C until use.
Embryos that were used for immunohistochemistry with the polyclonal antibody Wt1 were frozen unfixed in liquid N 2-cooled isopentane, and 10-m cryosections were cut on a cryostat. Before immunostaining, the sections were fixed with methanol/acetone 1:1 at Ϫ20°C for 10 min.
For immunofluorescence and immunohistochemistry, cryosections were rehydrated in Tris-PBS (TPBS) and blocked for nonspecific binding with 16% sheep serum, 1% bovine albumin, and 0.1% Triton X-100 in TPBS. Primary antibodies used are detailed in Table 1 .
When biotinylated secondary antibodies were used, endogenous biotin was blocked with the Avidin-Biotin blocking kit from Vector.
Single immunofluorescence was performed by incubating the sections with the primary antibody overnight at 4°C, washing in TPBS, and incubating with the corresponding fluorochrome-conjugated secondary antibody for 1 h at room temperature. Secondary antibodies were not used in the case of the anti-CD34 and anti-CD45 antibodies, which were conjugated to eFluor660 and phycoerythrin, respectively. Nuclei were counterstained with DAPI (Sigma). Double immunofluorescence was performed by mixing both primary antibodies (rabbit polyclonal and mouse or rat monoclonal) and incubating overnight at 4°C. In the case of the double CD31/SMC-␣-actin immunostaining we incubated overnight the sections with the anti-CD31 antibody, then we blocked the sections with monovalent donkey anti-mouse IgG, and we incubated the sections again with the anti-SMC-␣-actin antibody, before incubation with fluorochrome-conjugated secondary antibodies. In the case of the double CD31/CD34 immunostaining we incubated the sections overnight with the anti-CD31 antibody, then with a biotin-conjugated anti-rat IgG antibody followed by incubation with TRITC-conjugated extravidin. We saturated the sections with rat IgG, and we finally incubated the sections with the eFluor660-conjugated anti-CD34 antibody. Negative controls were performed incubating with nonimmune rat, mouse, or rabbit IgG instead of the primary antibody.
WT1 immunohistochemistry was performed by incubating the sections with the primary rabbit anti-Wt1 antibody, a secondary biotinylated anti-rabbit IgG antibody, and extravidin-peroxidase. Staining of the sections was performed with a diaminobenzidine kit (Sigma-Aldrich).
Time-lapse microscopy. E11.5 Wt1 cre /ROSA26R-EYFP mouse embryos were dissected in PBS supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 g/ml). Lung buds were Cre / Rosa26R-EYFP neonates were excised, dissociated for 15 min at 37°C in prewarmed collagenase solution (0.1% in HBSS ϩ 3 mM CaCl 2) (Sigma), and homogenized by repeated pipetting. Cell suspension was washed in PBS plus 2% FBS and 10 mM HEPES. Then cells were incubated on ice at the dark with Cy5-conjugated rat anti-mouse CD31, Alexa 660-conjugated rat anti-mouse CD34, and Cy5-conjugated rat anti-mouse Sca-1. After washing, the cells were analyzed in a MoFlo cell sorter. Damaged cells were excluded from the results by propidium iodide staining.
Image analysis. Quantification of Wt1 cre -YFP cell abundance was performed by splitting green (YFP) and blue (DAPI) channels and expressing the area of the YFP ϩ spots as percentage of the total area occupied by the nuclei stained with DAPI. The measurements were made with ImageJ software. Three to four images were used for each developmental stage. The proportion of the Wt1 cre -YFP cells respect to the CD31 ϩ was calculated by manually counting double stained and single stained cells on three to four images for each developmental stage. All the results were expressed as means Ϯ SE. (Fig. 1D) . Immunolocalization of Wt1 protein in Wt1 GFP/ ϩ E12.5 embryos, where GFP is a reporter of the Wt1 gene, also confirmed restricted expression of Wt1 to the mesothelium (Fig. 1E) .
RESULTS

Wt1
Since the Cre driver used (mWt1/IRES/GFP-Cre) induces the expression of low levels of GFP, we checked whether this expression could be interfering with the YFP expression of the reporter. Control Wt1-Cre ϩ/ϩ ; Rosa26R-EYFP Ϫ/Ϫ embryos show no detectable GFP levels in the lung tissue by confocal microscopy (Fig. 1F) . Thus the green fluorescence detected in the tissues is exclusively attributable to the YFP reporter. Table 2) . At this stage, the primary pulmonary vascular plexus is starting its formation, and a few Wt1 cre -YFP cells also expressed endothelial markers such as CD31 (Pecam-1) and CD34 (Fig.  1 , G and H). They were not quantified because of their low abundance. Both markers always colocalized on the same cells (Fig. 1I) . We did not observe ␣-SMC actin-expressing smooth muscle cells within the lung buds by this stage (Fig. 1G) .
A more developed vascular plexus is present by the stages E12.5-E13.5 around the endodermal epithelium. As described in younger embryos, all the endothelial cells express both the CD31 and the CD34 markers (not shown). Colocalization of YFP with endothelial markers has become relatively frequent (Fig. 1, J and K) and reach ϳ9% of all the CD31 ϩ cells ( Table  2 ). The earliest smooth muscle cells, identified by ␣-SMC actin immunoreactivity, appear at the stage E12.5 around the main bronchia. Some of these muscular cells are YFP ϩ (Fig. 1J ). Wt1 cre -YFP cells become very abundant by the stage E13.5, and they appear incorporated to the vessels (Fig. 1K) and to the mesenchymal condensations that will give rise to the tracheal cartilages (Fig. 1L) .
The epithelial-mesenchymal transition of the pulmonary mesothelium was directly observed in Wt1 cre /ROSA26R-EYFP E11.5 embryos by time-lapse confocal microscopy of explanted lung buds (Fig. 2) . YFP-expressing cells were observed clearly migrating from the mesothelium as the endodermal epithelium was growing and forming branches. 
The results of the quantification of Wt1 cre -YFP cells by image analysis and flow cytometry are expressed as means Ϯ SE; n.c., not calculated. Neo, neonate. highly developed vascular network is present throughout the lung. Wt1 cre -YFP cells can be found incorporated to the vascular endothelium of this network, expressing CD31 and CD34 (Fig. 3, A, C, and D) . The relative abundance of Wt1 cre -YFP cells reaches its maximum by E16.5, although the proportion of the YFP ϩ /CD31
ϩ cells (ϳ25% of all the endothelial cells) is about the same in E14.5 and E16.5 stages (Table 2 ). Airway and vascular smooth muscle can be identified by ␣-SMC actin immunoreactivity. In both cases, Wt1 cre -YFP cells appear incorporated to the smooth muscle layers (Fig. 3, B and C) . The fibroblast marker FSP1 appears in cells of the developing lungs at the stage E16.5, but colocalization with YFP was not observed (Fig. 3F) .
The presence of Wt1 cre -YFP cells in the vascular walls, including those from the large arteries and veins, is frequent by the end of the gestation (Fig. 3, E, G, and H) . However, their relative abundance and their contribution to the vascular endothelium have decreased by E18.5 ( Table 2) . Wt1
cre -YFP cells contribute to the pulmonary cartilage and also to CD34
ϩ fibroblast-like cells. In the latest gestational stages the microvascular endothelial cells are still expressing CD34, although the endothelium of more mature vessels shows a decrease in the expression of this marker (Fig. 3E) . Furthermore, a number of CD34 ϩ
/CD31
Ϫ fibroblast-like cells appear now in the pulmonary interstitium. Wt1 cre -YFP cells are frequently localized within this fibroblast-like cell population (Fig. 3, E and I) . These CD34 ϩ cells were negative for the stem cell factor receptor c-Kit (Fig. 3, K and L) . Wt1 cre -YFP rounded cells also appear within the cartilaginous condensations of the trachea and bronchi (Fig. 3, I and J). Chondrocytic differentiation of these Wt1 cre -YFP cells was confirmed with Alcian blue staining (Fig. 3M) . Table  2) . Some of them show expression of endothelial markers (Fig. 4, A and B) , but the high abundance of CD31 ϩ cells in the neonatal lungs precluded quantification by image analysis. Thus we quantified them by flow cytometry as described below. The expression of the fibroblast marker FSP1 is now more abundant, but colocalization with YFP is very infrequent (Fig. 4C) .
We analyzed sections of lungs of 3-mo-old Wt1 cre /ROSA-EYFP mice, where some Wt1 cre -YFP cells are still found. As in the embryos, Wt1 cre -YFP cells express CD31 and CD34, and many appear incorporated to the vasculature, but we could not find clear colocalization of YFP with FSP1 (Fig. 4, D-F) .
Since FSP1 was not colocalized with YFP, suggesting a specific origin for the FSP1 ϩ cell population, we colocalized this marker with the leukocyte common antigen CD45. Most of the isolated FSP1 ϩ cells in E18.5 embryos and in neonates are CD45 ϩ (Fig. 4, G-I) . Surprisingly, the tunica media of some arteries is also FSP1
ϩ , but these smooth muscle cells are always YFP Ϫ (Fig. 4G) . We studied the proliferation of the Wt1 cre -YFP cells by colocalization with the marker of mitotic cells PH3 (phosphohistone-3) (Fig. 4, J-L) . In E12.5 embryos, most proliferating Wt1 cre -YFP cells are located in the mesothelium (Fig. 4 , J and K). Some YFP Ϫ endothelial cells are also positive for PH3 by this stage. However, in E18.5 embryos, PH3 immunoreactivity is scarce in the lungs, and it was not found in Wt1 cre -YFP nor in endothelial cells (Fig. 4L) .
In neonates, colocalization of YFP with the endothelial markers CD31, CD34, and Sca-1 was quantified by flow cytometry analysis. A representative experiment is shown in Fig. 5 , and the results of three different experiments are summarized in Ϫ/Ϫ embryos can reach in the genetic background that we used for this study. The gross morphology of the Wt1 Ϫ/Ϫ lungs is anomalous, showing a rounded transverse section and abnormal fusion of the lobes (Fig. 6, A, B, N, and O). The accessory lobe is mislocated at the right of the mediastinum because of a defect in the pleuropericardic septum. A diaphragmatic defect is also evident, leading sometimes to pulmonary hernia (Fig. 6, B and C) . The pleural cavities are also abnormal, small, round-shaped, and widely open to the peritoneal cavity. The pleural walls are abnormally populated by cells (asterisks in Fig. 6, A and B) . The pulmonary mesothelium of the mutant mice shows a complete basal lamina when stained with Sirius red. This continuous basal lamina is not observed in the control embryos (Fig. 6, D and E) . The existence of the basal lamina in the mutant embryos was confirmed by laminin immunoreactivity (Fig. 6, F and G) . Since this could suggest a blockade of the migration of cells from the mesothelium to the pulmonary mesenchyme, a process that involves degradation of the basal lamina, we checked the expression of vimentin, a mesenchymal marker, and we observed a much reduced number of vimentin-positive cells in the mutants compared with the control littermates. Additionally, the mesothelium of the control is vimentin immunoreactive, different from the mesothelium of the Wt1 Ϫ/Ϫ lungs (Fig.  6, H and I) . FGF9 immunoreactivity was also decreased in the mesenchyme and in the mesothelium of the mutant lungs. Expression in the pulmonary endodermal epithelium and in the neural tissue was similar in mutant and in control embryos (Fig. 6, J-M ).
DISCUSSION
Although it had been already shown that the Wt1 gene is involved in the development of many organs (14, 19, 21, 25, 28) , no information was hitherto available about the role played by Wt1 in lung development. The specific expression site of Wt1 is the mesothelium lining the pulmonary sacs, as shown by previous reports (35) and confirmed by our results. Thus Wt1 is a reliable marker of the cells delaminated from the mesothelium through an epithelial-mesenchymal transition. The contribution of cells from the Wt1 lineage cells to the embryonic lung had been previously demonstrated by using a Wt1 cre transgenic mouse line (35) , but only the origin of pulmonary vascular smooth muscle and a mesenchymal cell population from Wt1-expressing cell lineage could be demonstrated in this report.
The pulmonary mesenchyme, therefore, has a dual origin, from the preexisting, non-Wt1-expressing splanchnopleural mesoderm that surrounds the endodermal sprouts and from the Wt1-expressing mesothelium. We have herein shown evidence that this second population is quantitatively relevant and it has a much wider differentiation potential than previously described. This potential included endothelium, smooth muscle from vessels and bronchia, CD34 ϩ fibroblast-like cells, and tracheal/bronchial cartilage. As far as we know, this is the first time that chondrocytes are shown to derive from Wt1-expressing, mesothelium-derived cells. Our findings emphasize the wide potential of differentiation of the mesothelial-derived cells, possibly related with the gain of multipotentiality after an epithelial-mesenchymal transition (4).
Lung bud development in mice begins at E9.5 (9), and we have already found Wt1 cre -YFP cells by the stage E10.5, when Wt1 is already strongly expressed in the mesothelium lining the lung primordia. Since the earliest stages of development we can observe the presence of Wt1 cre -YFP forming part of the early vascular plexus, expressing the endothelial cell marker CD31 (PECAM-1). Moreover, Wt1
cre -YFP cells also express CD34, another marker of the developing endothelium. Pulmonary vasculogenesis occurs by assemblage of progenitors residing in the pulmonary mesenchyme (1, 13) . We have demonstrated that two different components (splanchnopleural and mesothelium-derived) contribute to these progenitors. Although the abundance of Wt1 cre -YFP cells peaks by midgestation (especially by E16.5) and declines by the end of gestation, our flow cytometry analysis shows that even in neonates Wt1 cre -YFP cells still account for more than 3% of all the pulmonary endothelial cells as demonstrated by colocalization of CD31 and Sca-1 with YFP. It is important to remark that Sca-1 is expressed in pulmonary endothelial cells of the mice (20) . The decrease of the abundance of the YFP ϩ endothelium during the late gestation cannot be attributed to an increased proliferation of the YFP Ϫ endothelium, according to the low levels of mitotic endothelial cells found in E18.5 embryos. Thus we think that recruitment of circulating endothelial progenitors and/or YFP-negative mesenchymal angioblasts might be a source of new endothelial cells in the developing lung vasculature, diluting the original Wt1 cre -YFP population. In late gestational stages, CD34 expression is observed in CD31-negative, fibroblast-like cells, with long prolongations. These CD34 ϩ cells have been called "telocytes," and they had been described in the trachea and lungs (16, 34, 44) . However, different from what has been described for telocytes, we could not find c-Kit expression in these CD34 ϩ cells. We think that the pulmonary CD34 ϩ cells are the same interstitial fibroblastlike cells described in other parts of the gastrointestinal tract (33, 39) , whose function is still poorly known and deserves further study. The abundance of Wt1 cre -YFP cells within this CD34 ϩ population suggests that this is a main fate for the mesothelium-derived cells.
Isolated, fibroblast-like FSP1-expressing cells were negative for YFP. This was a surprising observation, given the wide differentiation potential of the Wt1 cre -YFP cells, similar to that of the splanchnopleural mesenchyme. We have obtained the same result in intestinal Wt1 cre -YFP cells (7) . The colocalization of FSP1 with the leukocyte common antigen CD45 suggests that these cells could originate from circulating progenitors of hematopoietic origin. Origin of fibroblasts from circulating cells (a cell type also known as fibrocyte) has been extensively described in processes of fibrosis and scarring (15) , being involved in pulmonary fibrosis (2) . Our results show that a fibrocyte population could already populate the lung in late fetal stages.
Given the importance of the epithelial-mesenchymal interplay in pulmonary development, and also the quantitative importance of the mesothelium-derived compartment of the lung mesenchyme, the normal development of the lungs might be dependent on the expression of Wt1. Interestingly, a case of bilateral renal agenesis, cardiac defects, and congenital pulmonary airway malformation in a human fetus has been associated with abnormal expression of Wt1 (24) . The pulmonary phenotype of the Wt1 Ϫ/Ϫ mouse embryos supports a previously undescribed role for this gene in lung morphogenesis. The anomalies found were mainly related to the shape and arrangement of the pulmonary lobes, which appeared rounded in transverse section and abnormally fused. Pleural cavities were abnormal in size and shape and widely open to the peritoneal cavity because of a diaphragmatic defect. We think that the epithelial-mesenchymal transition of the Wt1-null mesothelium is defective, as suggested by the premature formation of a basal lamina, the lack of vimentin immunoreactivity in the epithelial lining, and the decrease in the number of vimentinexpressing mesenchymal cells in the mutant lungs. Vimentin immunoreactivity of the normal mesothelium is an indicative of an active epithelial-mesenchymal transition (31) . This immunoreactivity was not detected in the mesothelium of the mutant. The existence of a strong basal laminin immmunoreactivity in the mutant coelomic epithelium by the stage E13.5 also supports a delayed or blocked contribution of mesothelium-derived cells to the pulmonary mesenchyme, since epithelialmesenchymal transition involves degradation of the basal lamina. Anyhow, the contribution of the mesothelium-derived cells by this stage is still limited, according our data. For this reason, we cannot discard that most of the anomalies found in the lungs can be secondary to an abnormal development of the pleural cavities, whose walls in Wt1 Ϫ/Ϫ embryos show an abundant cell population instead of the loose, poorly cellularized tissue noticeable in control embryos. The involvement of Wt1 for the development of the subcoelomic mesenchyme and the coelomic septa has been described (29) . The excessive cellularization of the pleural walls (where Wt1 is also expressed) can be related with a defective growth of the pleural cavities, thus affecting indirectly to the morphogenesis of the lung lobes. An additional factor to account for the abnormal development of the lungs in the Wt1 Ϫ/Ϫ embryo might be the downregulation of FGF9 expression in the mesothelium and mesenchyme, although expression in the mutant endoderm, where Wt1 is not expressed, is normal. Ϫ/Ϫ E13.5 embryo (E). A complete basal lamina is present in the mutant embryo (arrows). F and G: laminin immunoreactivity (in red) also shows a continuous and well-developed basal lamina in the mutant embryo (arrows in G), whereas laminin immunoreactivity is discontinuous and weak in the basal surface of the coelomic epithelium of the control (arrows in F). No differences are evident in the smooth muscle cells (blue). H and I: immunolocalization of the mesenchymal marker vimentin shows a reduced number of vimentin-positive cells in the lungs of the mutant (I) compared with the control (H). Note the vimentin immunoreactivity of the coelomic epithelium of the control (arrows in H), whereas the coelomic epithelium of the Wt1 Ϫ/Ϫ lungs is negative for vimentin (arrows in I). J-M: immunolocalization of FGF9 in control (J) and Wt1 Ϫ/Ϫ (K) E12.5 embryos. FGF9 immunoreactivity is lower in the pulmonary mesenchyme and particularly in the mesothelium (arrows). However, the FGF9 immunoreactivity in the endodermal epithelium and in the neural tissue (L and M) is similar in control and mutant embryos. NT, neural tube; DRG, dorsal root ganglion. N and O: isolated lungs of control and Wt1 Ϫ/Ϫ E11.5 embryos. Mutant lung lobes are narrower and show abnormal lobe anatomy. Scale bars ϭ 25 m, except for A-C (100 m).
In conclusion, our results provide novel data on the heterogeneity and the different developmental origin of the mesenchymal cells involved in lung morphogenesis in mammals, and this could be useful in terms of understanding mesenchymalepithelial interactions during pulmonary development as well as congenital pulmonary defects including diaphragmatic hernia. The potential of the adult pulmonary mesothelium as a source of progenitors in cell therapy of pulmonary diseases is an open question, given the stem cell-like differentiation potential of the embryonic mesothelium-derived cells that we have herein shown. In a closely related case, such as the potential of the adult cardiac mesothelium (i.e., the epicardium), recent results have attracted attention on this possibility (22 
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